The partnership comprises a technology transfer of the current drug product manufacturing process for the Chikungunya Vaccine, with the option to transfer the drug substance process at a later stage
The Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine is approved for active immunization against smallpox, Mpox, and related orthopoxvirus infections in adults aged 18 and older. It is administered as a 2-dose injection, with doses spaced 4 weeks apart.
